MX2020011027A - Constructos de anticuerpos biespecíficos trivalentes. - Google Patents

Constructos de anticuerpos biespecíficos trivalentes.

Info

Publication number
MX2020011027A
MX2020011027A MX2020011027A MX2020011027A MX2020011027A MX 2020011027 A MX2020011027 A MX 2020011027A MX 2020011027 A MX2020011027 A MX 2020011027A MX 2020011027 A MX2020011027 A MX 2020011027A MX 2020011027 A MX2020011027 A MX 2020011027A
Authority
MX
Mexico
Prior art keywords
antibody constructs
trispecific antibody
trivalent trispecific
constructs
trivalent
Prior art date
Application number
MX2020011027A
Other languages
English (en)
Inventor
Lucas Bailey
Bryan Glaser
Qufei Li
Roland Green
Dileep Kumar Pulukkunat
Malgorzata Agnieszka Nocula-Lugowska
Daniel Justin Gerhardt
Original Assignee
Invenra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invenra Inc filed Critical Invenra Inc
Publication of MX2020011027A publication Critical patent/MX2020011027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se presentan constructos de anticuerpo trivalentes específicos, composiciones farmacéuticas que comprenden los constructos y métodos de uso de los mismos.
MX2020011027A 2018-04-17 2019-04-17 Constructos de anticuerpos biespecíficos trivalentes. MX2020011027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659047P 2018-04-17 2018-04-17
PCT/US2019/027816 WO2019204398A1 (en) 2018-04-17 2019-04-17 Trivalent trispecific antibody constructs

Publications (1)

Publication Number Publication Date
MX2020011027A true MX2020011027A (es) 2021-01-15

Family

ID=68240367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011027A MX2020011027A (es) 2018-04-17 2019-04-17 Constructos de anticuerpos biespecíficos trivalentes.

Country Status (10)

Country Link
US (1) US20210179734A1 (es)
JP (1) JP2021521781A (es)
KR (1) KR20200143730A (es)
CN (1) CN112384243A (es)
AU (1) AU2019255270A1 (es)
BR (1) BR112020021279A2 (es)
CA (1) CA3097605A1 (es)
IL (1) IL278073A (es)
MX (1) MX2020011027A (es)
WO (1) WO2019204398A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851488B2 (en) * 2015-11-03 2023-12-26 Ambrx, Inc. Anti-CD3-folate conjugates and their uses
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
MY192312A (en) * 2013-02-26 2022-08-17 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
KR102376287B1 (ko) * 2014-04-02 2022-03-17 에프. 호프만-라 로슈 아게 다중특이적 항체 경쇄 잘못짝짓기의 검출 방법
CN113549153A (zh) * 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
PL3221357T3 (pl) * 2014-11-20 2020-11-02 F. Hoffmann-La Roche Ag Wspólne łańcuchy lekkie i sposoby zastosowania
BR112017010324A2 (pt) * 2014-11-20 2018-05-15 F. Hoffmann-La Roche Ag método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
EP3313890A1 (en) * 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
US20170096485A1 (en) * 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
SG11201808911SA (en) * 2016-04-13 2018-11-29 Sanofi Sa Trispecific and/or trivalent binding proteins
MY198114A (en) * 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof

Also Published As

Publication number Publication date
JP2021521781A (ja) 2021-08-30
CN112384243A (zh) 2021-02-19
WO2019204398A1 (en) 2019-10-24
AU2019255270A1 (en) 2020-11-19
US20210179734A1 (en) 2021-06-17
CA3097605A1 (en) 2019-10-24
EP3781205A1 (en) 2021-02-24
BR112020021279A2 (pt) 2021-04-13
KR20200143730A (ko) 2020-12-24
IL278073A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2020013169A (es) Conjugados de camptotecina.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2022004304A (es) Agentes inductores de apoptosis.
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12020551716A1 (en) Anti-ror antibody constructs
MX2019007020A (es) Anticuerpos il-11.
MY191581A (en) Anti-pd-1 antibodies
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2019004690A (es) Constructos de anticuerpos.
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2020007748A (es) Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES